Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Real-world experience with eculizumab and switching to ravulizumab for generalized myasthenia gravis.
Tokuyasu D, Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, Kubota T, Samukawa M, Sugimoto T, Ishizuchi K, Oyama M, Yasuda M, Akamine H, Onishi Y, Suzuki Y, Kawaguchi N, Minami N, Kimura T, Takahashi MP, Murai H, Utsugisawa K. Tokuyasu D, et al. Among authors: ishizuchi k. Ann Clin Transl Neurol. 2024 May;11(5):1338-1346. doi: 10.1002/acn3.52051. Epub 2024 Apr 4. Ann Clin Transl Neurol. 2024. PMID: 38572524 Free PMC article.
Therapeutic Responses to Efgartigimod for Generalized Myasthenia Gravis in Japan.
Suzuki S, Uzawa A, Nagane Y, Masuda M, Konno S, Kubota T, Samukawa M, Ishizuchi K, Tokuyasu D, Handa H, Yasuda M, Kawaguchi N, Kimura T, Suzuki Y, Sugimoto T, Minami N, Takahashi MP, Murai H, Utsugisawa K. Suzuki S, et al. Among authors: ishizuchi k. Neurol Clin Pract. 2024 Jun;14(3):e200276. doi: 10.1212/CPJ.0000000000200276. Epub 2024 Mar 25. Neurol Clin Pract. 2024. PMID: 38544885 Free PMC article.
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
Bril V, Drużdż A, Grosskreutz J, Habib AA, Mantegazza R, Sacconi S, Utsugisawa K, Vissing J, Vu T, Boehnlein M, Bozorg A, Gayfieva M, Greve B, Woltering F, Kaminski HJ; MG0003 study team. Bril V, et al. Lancet Neurol. 2023 May;22(5):383-394. doi: 10.1016/S1474-4422(23)00077-7. Lancet Neurol. 2023. PMID: 37059507 Clinical Trial.
Proteolytic ectodomain shedding of muscle-specific tyrosine kinase in myasthenia gravis.
Mori S, Suzuki S, Konishi T, Kawaguchi N, Kishi M, Kuwabara S, Ishizuchi K, Zhou H, Shibasaki F, Tsumoto H, Omura T, Miura Y, Mori S, Higashihara M, Murayama S, Shigemoto K. Mori S, et al. Among authors: ishizuchi k. Exp Neurol. 2023 Mar;361:114300. doi: 10.1016/j.expneurol.2022.114300. Epub 2022 Dec 13. Exp Neurol. 2023. PMID: 36525997 Free article.
16 results